An In Situ Depot for Continuous Evolution of Gaseous H2 Mediated by a Magnesium Passivation/Activation Cycle for Treating Osteoarthritis
Lists
Only you see this
Abstract
Inflammation is involved in many human pathologies, including osteoarthritis (OA). Hydrogen (H<sub>2</sub> ) is known to have anti-inflammatory effects; however, the bioavailability of directly administered H<sub>2</sub> gas is typically poor. Herein, a local delivery system that can provide a high therapeutic concentration of gaseous H<sub>2</sub> at inflamed tissues is proposed. The delivery system comprises poly(lactic-co-glycolic acid) microparticles that contain magnesium powder (Mg@PLGA MPs). Mg@PLGA MPs that are intra-muscularly injected close to the OA knee in a mouse model can act as an in situ depot that can evolve gaseous H<sub>2</sub> continuously, mediated by the cycle of passivation/activation of Mg in body fluids, at a concentration that exceeds its therapeutic threshold. The analytical data that are obtained in the biochemical and histological studies indicate that the proposed Mg@PLGA MPs can effectively mitigate tissue inflammation and prevent cartilage from destruction, arresting the progression of OA changes.
BibTeX
@inproceedings{wan2018situ,
author = {Wei‐Lin Wan and Yu‐Jung Lin and Po‐Chien Shih and Yu‐Ru Bow and Qinghua Cui and Yen Chang and Wei‐Tso Chia and Hsing‐Wen Sung},
title = {{An In Situ Depot for Continuous Evolution of Gaseous H<sub>2</sub> Mediated by a Magnesium Passivation/Activation Cycle for Treating Osteoarthritis}},
booktitle = {Angewandte},
year = {2018},
doi = {10.1002/anie.201806159},
}Loading related content...